CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Name: CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
Published: 2019
License: Public Domain

Xijing Hospital · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

lymphoma

leukemia lymphocytic acute (all) in relapse, leukemia lymphocytic acute (all) refractory, lymphoma, b-cell, cd19 positive, leukemia lymphocytic acute, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Related documents